The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis

Reference

• Galliker NA, Murer C, Kamarashev J, et al. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol 2015;25:177–180.
   PubMed Web of Science ®Google Scholar
• Mai R, Zhou S, Zhong W, et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget 2015;6:28502–28512.
   PubMed Web of Science ®Google Scholar
• Berrocal A, Espinosa E, Marín S, et al. Spanish multidisciplinary melanoma group (GEM) guidelines for the management of patients with advanced melanoma. Eur J Dermatol 2015;25:392–403.
   PubMed Web of Science ®Google Scholar
• Queirolo P, Picasso V, Spagnolo F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 2015;41:519–526.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao TW, Hashizume R, et al. Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. J Neurooncol 2017;13:1–11.
   Google Scholar
• Livingstone E, Zimmer L, Vaubel J, et al. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chinese Clin Oncol 2014;3:29–47.
   PubMedGoogle Scholar
• Abdelrahman O, Elhalawani H, Ahmed H. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol 2015;11:3307–3319.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Klimek VM, Gaskell AA, et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies. Cancer Discov 2014;4:538–545.
   PubMed Web of Science ®Google Scholar
• Bilgiç Ö. Vemurafenib-induced pityriasis amiantacea: a case report. Cutan Ocul Toxicol 2015;35:329–331.
   PubMed Web of Science ®Google Scholar
• Yanik ME, Erfan G, Albayrak H, et al. Acitretin-induced spiny follicular hyperkeratosis. Cutan Ocul Toxicol 2015;35:165–167.
   PubMed Web of Science ®Google Scholar
• Hardefeldt PJ, Edirimanne S, Eslick GD. Deodorant use and the risk of skin toxicity in patients undergoing radiation therapy for breast cancer: a meta-analysis. Radiother Oncol 2012;105:378–379.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Antibiotic prophylaxis for skin toxicity induced by anti-EGFR agents: a systematic review and meta-analysis. Brit J Dermatol 2016;175:1166–1174.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877–1888.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014;32:3697–3704.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–451.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867–1876.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Mcarthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced, BRAF, V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248–1260.
   PubMed Web of Science ®Google Scholar
• Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF (V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014;15:954–965.
   PubMed Web of Science ®Google Scholar
• Dan CF, Mahalingam M. Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset. Am J Clin Dermatol 2013;14:461–471.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Kwan V, Miller DK, et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol 2015;33:52–56.
   PubMed Web of Science ®Google Scholar
• Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286–1299.
   PubMed Web of Science ®Google Scholar
• Liu M, Yang X, Liu J, et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget 2017;8:32258–32269.
   PubMedGoogle Scholar
• Mor JM, Heindl LM. Systemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma. Ocular Oncol & Pathol 2017;3:133–141.
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Jhaveri KD, Deray G, et al. Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. CKJ 2016;9:245–251.
   PubMed Web of Science ®Google Scholar
• Spagnolo F, Picasso V, Spano L, et al. Update on metastatic uveal melanoma: progress and challenges. Biodrugs 2016;30:161–172.
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189–196.
   PubMed Web of Science ®Google Scholar
• Schmid S, Siano M, Joerger M, et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2015;87:85–87.
   PubMed Web of Science ®Google Scholar
• Belum VR, Fontanilla PH, Lacouture ME, et al. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol 2013;9:1161–1170.
   PubMed Web of Science ®Google Scholar
• Cebollero A, Puértolas T, Pajares I, et al. Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Oncol 2016;5:458–462.
   Web of Science ®Google Scholar
• Boussemart L. Improved overall survival in melanoma with combined abrafenib and trametinib. N Engl J Med 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Viarisio D, Müller-Decker K, Hassel J, et al. The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice. J Invest Dermatol 2016;137:261–264.
   PubMed Web of Science ®Google Scholar
• Manousaridis I, Mavridou S, Goerdt S, et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol 2013;27:11–18.
   Web of Science ®Google Scholar
• Delea TE, Amdahl J, Wang A, et al. Cost effectiveness of dabrafenib as a first-line trEATMENT IN PATIENTS WITH BRAF, V600 mutation-positive unresectable or metastatic melanoma in Canada. Pharmacoeconomics 2015;33:367–380.
   PubMed Web of Science ®Google Scholar
• Martin-Liberal J, Larkin J. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncol 2015;11:579–589.
   PubMed Web of Science ®Google Scholar
• Herms F, Kramkimel N, Regnierrosencher E, et al. Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients. Melanoma Res 2016;26:487–491.
   PubMed Web of Science ®Google Scholar